Coherus BioSciences Files 8-K/A Amendment
Ticker: CHRS · Form: 8-K/A · Filed: May 21, 2024 · CIK: 1512762
Sentiment: neutral
Topics: amendment, financial-reporting, exhibits
TL;DR
Coherus BioSciences filed an amendment to an 8-K, updating financial info from May 8th.
AI Summary
Coherus BioSciences, Inc. filed an 8-K/A on May 21, 2024, to amend a previous filing regarding financial statements and exhibits. The original event date reported was May 8, 2024. The company, formerly known as BioGenerics, Inc., is incorporated in Delaware and headquartered in Redwood City, California.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be important for investors to review for the most accurate company data.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or financial distress.
Key Numbers
- 001-36721 — SEC File Number (Identifier for Coherus BioSciences' filings)
- 27-3615821 — IRS Employer Identification Number (Tax identification for Coherus BioSciences)
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Registrant
- BioGenerics, Inc. (company) — Former company name
- Dennis M. Lanfear (person) — Contact person for business and mail address
- May 8, 2024 (date) — Date of earliest event reported
- May 21, 2024 (date) — Filing date
FAQ
What specific information is being amended in this 8-K/A filing?
The filing is an amendment to a previous 8-K report concerning 'Financial Statements and Exhibits', but the specific details of the amendment are not provided in the header information.
What was the original date of the event being reported?
The earliest event reported was on May 8, 2024.
When was this amendment filed with the SEC?
This amendment was filed on May 21, 2024.
What is the principal executive office address for Coherus BioSciences, Inc.?
The principal executive offices are located at 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
What was Coherus BioSciences, Inc. formerly known as?
The company was formerly known as BioGenerics, Inc.
Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-05-21 17:14:58
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
Filing Documents
- chrs-20240508x8ka.htm (8-K/A) — 42KB
- chrs-20240508xex10d1.htm (EX-10.1) — 995KB
- chrs-20240508xex10d2.htm (EX-10.2) — 470KB
- 0001558370-24-008542.txt ( ) — 1885KB
- chrs-20240508.xsd (EX-101.SCH) — 4KB
- chrs-20240508_def.xml (EX-101.DEF) — 3KB
- chrs-20240508_lab.xml (EX-101.LAB) — 16KB
- chrs-20240508_pre.xml (EX-101.PRE) — 10KB
- chrs-20240508x8ka_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 10.1 Loan Agreement dated as of May 8, 2024 among Coherus BioSciences, Inc., the Guarantors, the Collateral Agent and the Lenders party thereto. 10.2 Revenue Participation Right Purchase and Sale Agreement dated as of May 8, 2024 among Coherus BioSciences, Inc. and Coduet Royalty Holdings, LLC. 104 Cover page Interactive Data file (embedded within the Inline XBRL document) Certain portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is not material and the registrant customarily and actually treats such information as private or confidential. Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon request by the SEC.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 21, 2024 COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: Chief Executive Officer